Hu Caiyun, He Bin, Gong Fengfeng, Liang Mingming, Zhao Dongdong, Zhang Guoliang
Department of Scientific Research, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Anhui, China.
Fuyang Hospital of Anhui Medical University, Anhui, China.
Front Pharmacol. 2022 Jan 27;13:764774. doi: 10.3389/fphar.2022.764774. eCollection 2022.
Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. However, no consensus has been reached on the security of LHQW to date. The current meta-analysis was performed to evaluate the safety profile of LHQW in relation to conventional drugs (PROSPERO CRD-42020224180). Comprehensive document retrieval was performed from both English and Chinese databases. Results were reported as risk ratio (RR) with 95% confidence interval (CI). Subgroup, sensitivity and meta-regression analyses were conducted to explore the possible sources of heterogeneity across eligible studies. In total, 217 experimental studies were included. For pooled studies, the incidence of adverse reactions was lower in the LHQW group than the conventional drug group (RR = 0.63, 95% CI = 0.58-0.69, < 0.001). In the evaluation of treating disease, significant reduced incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were detected in the LHQW group. In the evaluation of security indexes, LHQW group has a reduced incidence of respiratory system damage, skin and its appendages injury, nervous system damage and gastrointestinal system damage, along with other adverse reactions. Subgroup analysis additionally revealed a reduced incidence of some adverse reactions in the LHQW group compared to the conventional drug group (Rash of skin and its appendage damage, dizziness or headache owing to nervous system damage, nausea or vomiting from gastrointestinal system damage and resurgence of disease from other adverse reactions). The current study provides potential a reference for the security of LHQW. Further long-term high-quality studies are essential to validate our conclusions. https://clinicaltrials.gov/, CRD-42020224180.
连花清瘟胶囊/颗粒（LHQW）是一种对呼吸系统疾病具有潜在疗效的创新专利中药。然而，迄今为止，关于LHQW的安全性尚未达成共识。进行本次荟萃分析以评估LHQW相对于传统药物的安全性概况（PROSPERO CRD-42020224180）。从英文和中文数据库进行了全面的文献检索。结果以风险比（RR）和95%置信区间（CI）报告。进行亚组分析、敏感性分析和meta回归分析以探索合格研究中异质性的可能来源。总共纳入了217项实验研究。对于汇总研究，LHQW组的不良反应发生率低于传统药物组（RR = 0.63，95%CI = 0.58-0.69，<0.001）。在疾病治疗评估中，LHQW组在甲型H1N1流感和流感治疗期间的不良反应发生率显著降低。在安全性指标评估中，LHQW组呼吸系统损害、皮肤及其附属器损伤、神经系统损害和胃肠道系统损害以及其他不良反应的发生率降低。亚组分析还显示，与传统药物组相比，LHQW组某些不良反应的发生率降低（皮肤及其附属器损伤的皮疹、神经系统损害引起的头晕或头痛、胃肠道系统损害引起的恶心或呕吐以及其他不良反应引起的疾病复发）。本研究为LHQW的安全性提供了潜在参考。进一步的长期高质量研究对于验证我们的结论至关重要。https://clinicaltrials.gov/，CRD-42020224180。
